Loading
Led RELATIVITY-047, which made relatlimab the first approved LAG-3 inhibitor, and the trial that showed immunotherapy works in melanoma brain metastases.
Hussein Tawbi was principal investigator of RELATIVITY-047, which showed nivolumab plus relatlimab improves progression-free survival over nivolumab alone and led to the first approval of a LAG-3-targeted therapy, and of CheckMate 204, which showed nivolumab plus ipilimumab produces durable intracranial responses in melanoma brain metastases, changing their management. He leads brain metastasis research at MD Anderson.
Shares RELATIVITY-098, RELATIVITY-047, Relatlimab + nivolumab, LAG-3.
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Nivolumab, PD-1 and the tag melanoma.
Shares MD Anderson Cancer Center, Ipilimumab, Nivolumab, Melanoma and the tag melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Nivolumab, PD-1 and the tag melanoma.
Shares Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Nivolumab, PD-1 and the tag melanoma.
Shares Relatlimab + nivolumab, Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma.
Shares Ipilimumab, Nivolumab, PD-1, Melanoma and the tag melanoma.
Shares Ipilimumab, Nivolumab, PD-1, Melanoma and the tag melanoma.